The 5-year survival rate for pancreatic cancer patients is only 6%, the lowest of all major cancers, indicating a critical need for increased mechanistic understanding of pancreatic cancer development in order to identify new therapeutic targets. The c-Myc (Myc) oncoprotein is overexpressed in a variety of cancers, including pancreatic ductal adenocarcinoma (PDA), and generally correlates with poor prognosis. Through its global regulation of gene transcription, Myc helps regulate multiple oncogenic processes, including cancer cell intrinsic proliferation, survival, and adhesion/migration, as well as extrinsic tumor microenvironment remodeling including angiogenesis and immune cell reprogramming. The expression and activity of Myc is tightly regulated in normal cells. We have identified Serine 62 (S62) as a critical phosphorylation site, which increases the stability and DNA binding activity of Myc. S62 is phosphorylated downstream of RAS signaling; and activating mutations in KRAS are near universal driver mutations in PDA. The role of Myc in pancreatic cancer, however, is currently poorly understood. We have observed elevated levels of S62 phosphorylated Myc (pS62-Myc) in pancreatic cancer cell lines and primary pancreatic tumor samples. Furthermore, analysis of early precursor lesions (PanIN) peripheral to tumors also shows elevated pS62-Myc as compared to adjacent normal ducts. We have generated a novel mouse model, LSL-KRASG12D;ROSA-LSL-MycWT;Pdx1- or p48-Cre (KMC) mice, which shows that deregulated expression of Myc at physiologic levels is able to cooperate with mutant KRAS to accelerate acinar to ductal metaplasia (ADM), PanIN progression, and conversion to metastatic PDA. Importantly, our preliminary data indicate that KMC tumors develop common mutations seen in the evolution of the human disease, initiate a pronounced stromal reaction, show resistance to standard chemotherapy, and can progress to an aggressive, poorly differentiated PDA with a high metastatic rate. Further, we have established two therapeutics in the lab that target Myc post-translationally, both of which have shown promising activity against pancreatic cancer in vitro and in vivo. The overall hypothesis of this proposal is that KRAS-mediated phosphorylation of Myc at Serine 62 is an important driver of pancreatic cancer cell transformation, that this mechanism of activating Myc significantly contributes to the evolution of metastatic PDA, and that targeting post-translational activation of Myc has therapeutic efficacy in pancreatic cancer. The following aims are proposed:
Aim 1 : Elucidate the role of Myc and KRAS-mediated Serine 62 phosphorylation in the development of pancreatic cancer;
Aim 2 : Characterize KRAS/Myc-driven pancreatic tumor evolution, stromal expansion, heterogeneity, and therapeutic resistance;
Aim 3 : Establish the therapeutic efficacy of targeting post-translational activation of Myc for the treatment of pancreatic cancer. This work will reveal if phosphorylation of Myc downstream of KRAS plays a critical role in pancreatic cancer development and progression, and whether targeting this post-translational activation of Myc could have therapeutic value in the treatment of this devastating disease.

Public Health Relevance

Pancreatic cancer is one of the most deadly of all cancers and it is predicted to become the second leading cause of cancer related deaths by the year 2020. Thus, there is a critical need to increase our understanding of the molecular drivers that cause pancreatic cancer to identify new therapeutic targets. We have identified the c-Myc oncoprotein as an early driver of pancreatic cancer, which has allowed us to develop a new mouse model of pancreatic cancer for preclinical testing, and we are investigating two novel therapeutic approaches to target c-Myc activity to inhibit pancreatic cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA196228-02
Application #
9035381
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Watson, Joanna M
Project Start
2015-05-01
Project End
2020-04-30
Budget Start
2016-05-01
Budget End
2017-04-30
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Genetics
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Su, Yulong; Pelz, Carl; Huang, Tao et al. (2018) Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals. Genes Dev 32:1398-1419
Mellby, Linda D; Nyberg, Andreas P; Johansen, Julia S et al. (2018) Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. J Clin Oncol 36:2887-2894
Archer, Tenley C; Ehrenberger, Tobias; Mundt, Filip et al. (2018) Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. Cancer Cell 34:396-410.e8
McClinch, Kimberly; Avelar, Rita A; Callejas, David et al. (2018) Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. Cancer Res 78:2065-2080
Farrell, Amy S; Joly, Meghan Morrison; Allen-Petersen, Brittany L et al. (2017) MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nat Commun 8:1728
Sangodkar, Jaya; Perl, Abbey; Tohme, Rita et al. (2017) Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. J Clin Invest 127:2081-2090
Sears, Rosalie; Gray, Joe W (2017) Epigenomic Inactivation of RasGAPs Activates RAS Signaling in a Subset of Luminal B Breast Cancers. Cancer Discov 7:131-133
Mitrugno, Annachiara; Sylman, Joanna L; Ngo, Anh T P et al. (2017) Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC. Am J Physiol Cell Physiol 312:C176-C189
Janghorban, Mahnaz; Langer, Ellen M; Wang, Xiaoyan et al. (2017) The tumor suppressor phosphatase PP2A-B56? regulates stemness and promotes the initiation of malignancies in a novel murine model. PLoS One 12:e0188910

Showing the most recent 10 out of 14 publications